2 selected, source-linked Glucagon records carrying a 2017 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
The Federal Register published notice 2017-21202, attributed to FDA and its parent HHS department, on 2017-10-03. Its official title is “Abbreviated New Drug Applications for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of Recombinant Deoxyribonucleic Acid Origin; Draft Guidance for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide and Teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT02516150 at 2026-07-30T21:23:14.758Z. Its registry update date was 2017-08-31, and PeptideScanner's reviewed identity mapping was glucagon.